dual glp 1 gip receptor agonists This review summarizes how GLP-1 and GIP/GLP-1 act at the cellular level and their therapeutic applications in metabolic diseases like type 2 diabetes and obesity, highlighting advances in incretin-based Dual GIP–GLP1-Receptor Agonists In The

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.

GLP-1RA only reduced the risk of nonfatal stroke

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006

In recent years, weight-loss drugs have become a common addition to diet and exercise routines.

While their glycemic, weight-lowering, and cardiovascular benefits are well established through randomized trials and meta-analyses, concerns remain regarding their safety and tolerability across diverse populations and clinical settings